The MI-BET study will evaluate whether imaging, biomarkers, and clinical data can help tailor radioligand therapy based on individual patient response rather than a fixed treatment schedule.
GE HealthCare and Mayo Clinic announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a study designed to evaluate a more personalized approach to radioligand therapy for patients with advanced prostate cancer.
The collaboration stems from the organizations’ 2023 Strategic Radiology Research Alliance.
Radioligand therapy is a theranostics approach that combines targeted radiopharmaceutical diagnostics and therapies to identify and treat cancer. Many patients receiving radioligand therapy currently follow a standardized number of treatment cycles. The MI-BET study will evaluate whether imaging- and biomarker-informed insights can support adapting treatment based on an individual patient’s response over time, including the potential to pause therapy when appropriate.
The study will use GE HealthCare’s StarGuide SPECT/CT system alongside MIM Software’s MIM LesionID Pro to monitor tumor response throughout treatment. Researchers will integrate imaging data with clinical outcomes and blood-based biomarkers to evaluate whether these combined data can help inform treatment decisions and support the development of predictive markers for patient response.
“Personalizing therapy is both a scientific pursuit and an opportunity to expand patient access,” says Geoffrey Johnson, MD, PhD, chair of the radiopharmaceutical trial team at Mayo Clinic Comprehensive Cancer Center, in a release. “Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer. By evaluating response earlier in their treatment, we can generate data to drive approaches that could help reduce unnecessary therapy while expanding access to care for wider populations.”
The study will be conducted at Mayo Clinic’s Rochester, Minnesota, campus. Researchers also plan to investigate GE HealthCare’s next-generation StarGuide GX SPECT/CT technology, which is designed to evaluate the potential for shorter scan times and more precise tumor assessment.
StarGuide GX has received CE mark but has not been cleared by the US Food and Drug Administration and is not available for sale in the United States.
Photo caption: MIM LesionID Pro
File photo/GE HealthCare
